Literature DB >> 7586215

Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy.

J Sadoshima1, S Izumo.   

Abstract

It has been suggested that phosphorylation of a 40S ribosomal protein, S6, regulates protein synthesis. Two distinct families of S6 kinase have been identified, the rsk-encoded 85- to 92-kD S6 kinase (RSK) and the 70- or 85-kD S6 kinase (p70S6K). We have previously shown that hypertrophic stimuli, such as angiotensin II (Ang II), rapidly activate RSK in cardiac myocytes. However, RSK and p70S6K are regulated by distinct mechanisms, and p70S6K, but not RSK, is the physiological S6 kinase in vivo in other cell types. Using cultured neonatal rat ventricular myocytes, we examined whether Ang II activates p70S6K and investigated the effect of rapamycin, a potent yet indirect inhibitor of p70S6K, on the Ang II-induced hypertrophic response. Immunoblot analyses indicate that cardiac myocytes express the 70- and 85-kD forms of p70s6K. Ang II caused a rapid and sustained activation of p70S6K through the type I Ang II receptor. Rapamycin inhibited Ang II-induced activation of p70S6K in a dose-dependent manner, with an IC50 of 0.14 ng/mL (0.15 nmol/L). Rapamycin did not inhibit Ang II-induced activation of tyrosine kinase, mitogen-activated protein kinase, RSK, and protein kinase C. The effect of rapamycin is unlikely to be mediated by its effect on p34cdc2 and p33cdk2 because Ang II did not activate these cell cycle-dependent kinases in cardiac myocytes. In contrast, a dose-dependent inhibition of p70S6K by rapamycin is very closely correlated with its inhibition of the Ang II-induced increase in protein synthesis. Interestingly, rapamycin did not affect the Ang II-induced activation of specific gene expression, including the immediate-early gene c-fos and fetal type genes, such as atrial natriuretic factor and skeletal alpha-actin. Moreover, rapamycin did not suppress Ang II-induced phenotypic changes at the protein level, such as increased atrial natriuretic factor secretion, expression of beta-myosin heavy chain, and organization of actin into sarcomeric units. These results indicate that p70S6K is activated by Ang II and that a rapamycin-sensitive signaling mechanism, most likely p70S6K, plays an essential role in the Ang II-induced increase in overall protein synthesis but not in Ang II-induced specific phenotypic changes in cardiac myocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586215     DOI: 10.1161/01.res.77.6.1040

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  54 in total

1.  Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload.

Authors:  T Senbonmatsu; S Ichihara; E Price; F A Gaffney; T Inagami
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  The conserved phosphoinositide 3-kinase pathway determines heart size in mice.

Authors:  T Shioi; P M Kang; P S Douglas; J Hampe; C M Yballe; J Lawitts; L C Cantley; S Izumo
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  IGF-I activates the eIF4F system in cardiac muscle in vivo.

Authors:  Thomas C Vary; Charles H Lang
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

4.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

5.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.

Authors:  Jo El J Schultz; Sandra A Witt; Betty J Glascock; Michelle L Nieman; Peter J Reiser; Stacey L Nix; Thomas R Kimball; Thomas Doetschman
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

6.  Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy.

Authors:  Mitsutaka Yamamoto; Guiping Yang; Chull Hong; Jing Liu; Eric Holle; Xianzhong Yu; Thomas Wagner; Stephen F Vatner; Junichi Sadoshima
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 7.  The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus.

Authors:  Tomohiro Suhara; Yuichi Baba; Briana K Shimada; Jason K Higa; Takashi Matsui
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

Review 8.  Rapalogs and mTOR inhibitors as anti-aging therapeutics.

Authors:  Dudley W Lamming; Lan Ye; David M Sabatini; Joseph A Baur
Journal:  J Clin Invest       Date:  2013-03-01       Impact factor: 14.808

Review 9.  Validation of anti-aging drugs by treating age-related diseases.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2009-03-28       Impact factor: 5.682

10.  Altered regulation of contraction-induced Akt/mTOR/p70S6k pathway signaling in skeletal muscle of the obese Zucker rat.

Authors:  Anjaiah Katta; Sunil Kakarla; Miaozong Wu; Satyanarayana Paturi; Murali K Gadde; Ravikumar Arvapalli; Madhukar Kolli; Kevin M Rice; Eric R Blough
Journal:  Exp Diabetes Res       Date:  2010-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.